Tafenoquine

[Guest guest]

Tafenoquine being the WR238605 of the "hamster study" ie the most effective at clearing babesia in hamsters (see table 3 of the "hamster study"), do we know why it isn't being discussed by LLMDs as a potential agent against Babesia?

I still can't find it in my French pharmaceuticals data base. I can find primaquine which it is related to it (an earlier version?) but not tafenoquine.

Nelly

PS: Barb, as you know, I am well aware that combos of abx and other agents like HCQ are the way to go, well aware that what info we get from the studies have to be adapted by educated guesswork to help in our own specific situation.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve & db=pubmed & list_uids=10885356 & dopt=Abstract

Lancet. 2000 Jun 10;355(9220):2041-5.

Related Articles,

Links

Malaria chemoprophylaxis with tafenoquine: a randomised study.Lell B, Faucher JF, Missinou MA, Borrmann S, Dangelmaier O, Horton J, Kremsner PG.Research Unit, Albert Schweitzer Hospital, Lambarene, Gabon.BACKGROUND: Tafenoquine is an analogue of primaquine with an improved therapeutic and safety profile. It has a long half-life and activity against liver-stage malaria parasites, so may be useful for chemoprophylaxis. In this randomised, double-blind study we assessed the efficacy and safety of tafenoquine in different doses. METHODS: 2144 individuals aged 12-20 years living in Lambarene, Gabon, an endemic area for Plasmodium falciparum malaria, were invited to take part. 535 attended, and 426 eligible participants were randomly assigned tafenoquine (250 mg, 125 mg, 62.5 mg, or 31.25 mg) or placebo daily for 3 days. 417 received initial curative treatment with halofantrine, and 410 completed the assigned prophylaxis regimen. During follow-up of 70 days, adverse events were recorded and thick blood smears were examined weekly. The primary and secondary endpoints were the number of individuals with positive blood smears by day 56 and day 77, respectively. Analyses were per-protocol. FINDINGS: Eight positive blood smears were recorded by day 56 (four/82 participants in the placebo group; four/79 tafenoquine 31.25 mg group). By day 77, 34 positive blood smears had been recorded (14/82 placebo; 16/79 tafenoquine 31.25 mg; three/86 tafenoquine 62.5 mg; one/79 tafenoquine 125 mg; none/84 tafenoquine 250 mg). Numbers of adverse events did not differ significantly between the treatment groups. INTERPRETATION: Tafenoquine is effective and well tolerated. It has the potential to replace currently used drugs for malaria chemoprophylaxis.Publication Types:

Clinical Trial Randomized Controlled Trial PMID: 10885356 [PubMed - indexed for MEDLINE]